





What is claimed is:

1. Diarylalkene derivatives or diarylalkane derivatives of the following general formula (1), (2), (3) or (4), or pharmaceutically acceptable salts thereof:



wherein A represents -CH=CH-, -CH₂-CH₂-, -S-, -CH₂-S-, -S-CH₂-, -O-, -CH₂-O-, -O-CH₂-, -N(R¹⁷)-CH₂-, -CH₂-N(R¹⁷)-, -CH=CH-CH₂-, -CH₂-CH=CH-, -CH₂-CH₂-CH₂-, -N(R¹⁷)-(CO)-, -(CO)-N(R¹⁷)-, -(CO)-, -(SO)- or -C(R¹⁸R¹⁹)- wherein R¹⁷ represents H, a lower alkyl or an aryl, and R¹⁸ and R¹⁹ are each independently selected from the group consisting of H, a lower alkyl, an aryl and -C(O)OR¹⁵ wherein R¹⁵

represents a lower alkyl or an aryl;

a, b, c and d are each selected from the group consisting of CR¹ and CR²;
or one of a, b, c and d is N;

5 R¹, R² and R⁴ each independently represent H, a halogen, -CF₃, -OR¹⁴,
-COR¹⁴, -SR¹⁴, -S(O)_tR¹⁵, -N(R¹⁴)₂, -NO₂, -OC(O)R¹⁴, -CO₂R¹⁴, -OCO₂R¹⁴,
-CN, -NR¹⁴COOR¹⁵, -SR¹⁵C(O)OR¹⁵ or -SR¹⁵N(R¹⁶)₂ wherein R¹⁴
represents H, a lower alkyl, an aryl or an aryl-lower alkyl group, R¹⁵
represents a lower alkyl or an aryl group, R¹⁶ is independently selected
from the group consisting of H and -C(O)OR¹⁵, and t represents 1 or 2;

10 R³ represents H;

V-W represents C=C, CH-CH, CH-N or N-CH;

Z is selected from the group consisting of C, CH and N (with the proviso
that when Z is C, the bond represented by a dotted line represents a
double bond and when Z is CH or N, the bond represented by the dotted
15 line represents a single bond;

n represents 0 to 3;

R⁵ and R⁶ each independently represent H, a halogen, -CF₃, a lower alkyl
or an aryl;

or R⁵ and R⁶ together form =O or =S;

20 Y¹ represents O or S;

B represents NR^{17a}, -NR^{17a}(CH₂)_vCHR²¹-, -(CH₂)_vCHR²¹- wherein v
represents 0 to 3, R^{17a} represents H, a lower alkyl or an aryl, R²¹
represents H, a lower alkyl, an aryl, a hydroxyl-lower alkyl, -CH₂SH,
-CH₂CH₂SCH₃, -CH₂(CO)NH₂, -CH₂CH₂(CO)NH₂, -(CH₂)_w-COOR²⁹,
25 -(CH₂)_w-NR²⁹R³⁰ wherein R²⁹ and R³⁰ each independently represent
hydrogen atom or a lower alkyl group, and w represents 0 to 4,
-(CH₂)₃NHC(NH₂)=NH, benzyl, 4-hydroxybenzyl, 3-indoylmethyl or
5-imidazoylmethyl;


G represents $-(CO)-$, $-(SO)-$, $-(SO_2)-$ or a covalent bond;

m represents 0 to 6;

Y^2 represents C or S;

p and q are each independently selected from the group consisting of 1, 2
5 and 3;

R^7 and R^8 each independently represent H, a lower alkyl, an aryl,
 $-(CO)R^{18a}$, $-(CS)R^{18a}$, $-(CO)NR^{18a}R^{19a}$, $-(CS)NR^{18a}R^{19a}$ wherein R^{18a}
represents H, a lower alkyl, an aryl or a cycloalkyl group which may
have a hetero atom in the ring, R^{19a} represents H, a lower alkyl or an
10 aryl; or R^{18a} and R^{19a} together form a cycloalkyl which may have a
halogen, $-CF_3$, a lower alkyl or an aryl as a substituent, $-(CO)OR^{20}$ or
 $-(CS)OR^{20}$ wherein R^{20} represents an alkyl group having 1 to 12 carbon
atoms, an aryl group or a cycloalkyl group which may have a hetero atom
in the ring, or a group of the following general formula (5):



(5)

wherein Y^4 and Y^3 each represent O or S; s represents 0 to 6;

E represents NR^{22} or CHR^{23} wherein R^{22} represents H, a lower alkyl or
aryl; and R^{23} represents H, a lower alkyl, an aryl, a hydroxyl-lower alkyl,
 $-CH_2SH$, $-CH_2CH_2SCH_3$, $-CH_2(CO)NH_2$, $-CH_2CH_2(CO)NH_2$, $-CH_2COOH$,
20 $-CH_2CH_2COOH$, $-(CH_2)_4NH_2$, $-(CH_2)_3NHC(NH_2)=NH$, benzyl,
4-hydroxybenzyl, 3-indoylmethyl or 5-imidazolymethyl;

R^{24} represents H, a lower alkyl or an aryl;


R²⁵ represents H, a lower alkyl, an aryl, -OR^{18a}, -(CO)R^{18a}, -(CS)R^{18a},
 -(CO)NR^{18a}R^{19a}, -(CS)NR^{18a}R^{19a}, -(CO)OR²⁰ or -(CS)OR²⁰ wherein R^{18a},
 R^{19a} and R²⁰ are as defined above,

R⁹ represents H, a lower alkyl, an aryl, -(CO)R^{18a}, -(CS)R^{18a},
 5 -(CO)NR^{18a}R^{19a}, -(CS)NR^{18a}R^{19a}, -(CO)OR²⁰ or -(CS)OR²⁰ wherein R^{18a},
 R^{19a} and R²⁰ are as defined above;

R¹⁰ represents H, a lower alkyl or an aryl;

R¹¹ represents H, a lower alkyl or an aryl;

R¹² represents H, a lower alkyl, an aryl, -(CO)R^{18a}, -(CS)R^{18a},
 10 -(CO)NR^{18a}R^{19a}, -(CS)NR^{18a}R^{19a}, -(CO)OR²⁰ or -(CS)OR²⁰ wherein R^{18a},
 R^{19a} and R²⁰ are as defined above, or a substituent represented by the
 following general formula (6):




wherein s¹ represents 1 to 6;

15 Y³ represents O or S,

R²⁶ represents H, a lower alkyl or an aryl;

R²⁷ represents H, a lower alkyl, an aryl, -OR^{18a}, -(CO)R^{18a}, -(CS)R^{18a},
 -(CO)NR^{18a}R^{19a}, -(CS)NR^{18a}R^{19a}, -(CO)OR²⁰ or -(CS)OR²⁰ wherein R^{18a},
 R^{19a} and R²⁰ are as defined above;

20 or R¹¹ and R¹² form a substituent represented by the following general
 formula (7) together with the nitrogen atom:



wherein Y^3 represents O or S, and R^{27} is as defined above.

2. Diarylalkene derivatives or diarylalkane derivatives, or pharmaceutically acceptable salts according to claim 1, wherein in the
5 above general formulae (1), (2), (3) and (4), the group represented by V-W is C=C, CH·CH or N·CH;

Z is selected from the group consisting of C, CH and N (with the proviso that when Z is C, the bond represented by a dotted line represents a double bond and when Z is CH or N, the bond represented by the dotted
10 line represents a single bond);

B represents NR^{17a} , CHR^{21} and CH_2CHR^{21} wherein R^{17a} represents H, a lower alkyl or an aryl, R^{21} represents H, a lower alkyl, an aryl, a hydroxyl-lower alkyl, $-CH_2SH$, $-CH_2CH_2SCH_3$, $-CH_2(CO)NH_2$,
15 $-CH_2CH_2(CO)NH_2$, $-CH_2COOH$, $-CH_2CH_2COOH$, $-(CH_2)_4NH_2$, $-(CH_2)_3NHC(NH_2)=NH$, benzyl, 4-hydroxybenzyl, 3-indoylmethyl or 5-imidazolymethyl; and

R^{18a} represents H, a lower alkyl or an aryl, and R^{19a} represents H, a lower alkyl or aryl; or R^{18a} and R^{19a} together form a cycloalkyl group which may have a halogen, $-CF_3$, a lower alkyl or an aryl as a
20 substituent, and R^{25} and R^{27} each represent H, a lower alkyl, an aryl, $-(CO)R^{18a}$, $-(CS)R^{18a}$, $-(CO)NR^{18a}R^{19a}$, $-(CS)NR^{18a}R^{19a}$, $-(CO)OR^{20}$ or $-(CS)OR^{20}$.

3. Diarylalkene derivatives or diarylalkane derivatives, or

pharmaceutically acceptable salts according to claim 2, wherein in the above general formulae (1), (2), (3) and (4),

A represents $-\text{CH}=\text{CH}-$, $-\text{CH}_2-\text{CH}_2-$, $-\text{S}-$, $-\text{CH}_2-\text{S}-$ or $-\text{S}-\text{CH}_2-$;

a, b, c and d each represent CH;

5 R^3 and R^4 each represent hydrogen atom;

R^5 and R^6 each represent hydrogen atom;

or R^5 and R^6 together form $=\text{O}$;

n represents 1 or 2;

Y^1 represents O;


10 B represents NR^{17a} , CHR^{21} or $\text{CH}_2\text{CHR}^{21}$ wherein R^{21} represents H, a lower alkyl, an aryl or $-\text{CH}_2\text{OH}$;

G represents $-(\text{CO})-$ or a covalent bond;

m represents 0 to 6;

p and q are each 1;

15 R^7 and R^8 each independently represent H, a lower alkyl, an aryl, $-(\text{CO})\text{R}^{18a}$ wherein R^{18a} represents H, a lower alkyl or an aryl, $-(\text{CO})\text{NR}^{18a}\text{R}^{19a}$ wherein R^{19a} represents H, a lower alkyl or an aryl; or R^{18a} and R^{19a} together form a cycloalkyl which may have a halogen, $-\text{CF}_3$, a lower alkyl or an aryl as a substituent, $-(\text{CO})\text{OR}^{20}$ wherein R^{20}
20 represents an alkyl group having 1 to 12 carbon atoms, an aryl group or a cycloalkyl group which may contain a hetero atom in the ring, or a group of the following general formula (8):



[wherein Y^4 and Y^3 each represent O;

s represents 1 or 2;

E represents CHR^{23} wherein R^{23} represents H,

5 R^{24} represents H;


R^{25} represents $-(CO)OR^{20}$;

R^9 represents $-(CO)OR^{20}$;

R^{10} represents H;

R^{11} represents H;

10 R^{12} represents a substituent represented by the following general formula (9);



wherein s^1 represents 2 or 3;


15 Y^3 represents O;

R^{26} represents H;

and R^{27} represents $-(CO)OR^{20}$,

or R^{11} and R^{12} form a substituent represented by the following general

formula (10) together with the nitrogen atom:



(10)

wherein Y^3 and R^{27} are as defined above.

4. Diarylalkene derivatives or diarylalkane derivatives, or
 5 pharmaceutically acceptable salts thereof according to claim 3, wherein
 in the above general formulae (1), (2), (3) and (4), A represents $-\text{CH}=\text{CH}-$
 or $-\text{CH}_2-\text{CH}_2-$,

a, b, c and d each represent CH;

R^1 and R^2 each represent H;

- 10 R^3 and R^4 each represent H;

V-W represents $\text{C}=\text{C}$;

n represents 2;

R^5 and R^6 each represent H; and

Y^1 represents O.

- 15 5. Diarylalkene derivatives or diarylalkane derivatives, or
 pharmaceutically acceptable salts thereof according to claim 1, wherein
 in the above general formulae (1), (2), (3) and (4),

V-W represents $\text{C}=\text{C}$, $\text{CH}-\text{CH}$ or $\text{N}-\text{CH}$;

- 20 Z is selected from the group consisting of C, CH and N (with the proviso
 that when Z is C, the bond represented by a dotted line represents a
 double bond and when Z is CH or N, the bond represented by the dotted
 line represents a single bond);

B represents $-(\text{CH}_2)_v-\text{CHR}^{21}$ wherein v represents 2 or 3, R^{21} represents H,

a lower alkyl, an aryl, a hydroxyl-lower alkyl, $-\text{CH}_2\text{SH}$, $-\text{CH}_2\text{CH}_2\text{SCH}_3$, $-\text{CH}_2(\text{CO})\text{NH}_2$, $-\text{CH}_2\text{CH}_2(\text{CO})\text{NH}_2$, benzyl, 4-hydroxybenzyl, 3-indoylmethyl or 5-imidazolymethyl; and

$\text{R}^{18\text{a}}$ represents H, a lower alkyl or an aryl, and $\text{R}^{19\text{a}}$ represents H, a lower alkyl or aryl; or $\text{R}^{18\text{a}}$ and $\text{R}^{19\text{a}}$ together form a cycloalkyl group which may have a halogen, $-\text{CF}_3$, a lower alkyl or an aryl as a substituent.

6. Diarylalkene derivatives or diarylalkane derivatives, or pharmaceutically acceptable salts thereof according to claim 5, wherein in the above general formula (1),

A represents $-\text{CH}=\text{CH}-$ or $-\text{CH}_2-\text{CH}_2-$;

a, b, c and d each represent CH;

R^1 , R^2 , R^3 , R^4 , R^5 and R^6 each represent H;


V-W represents $\text{C}=\text{C}$;

15 m represents 0 and n represents 2;

Y^1 represents O, G represents a covalent bond, and


R^7 and R^8 each independently represent H, a lower alkyl, $-(\text{CO})\text{R}^{18\text{a}}$ wherein $\text{R}^{18\text{a}}$ represents H, a lower alkyl or an aryl, $-(\text{CO})\text{OR}^{20}$ wherein R^{20} represents an alkyl group having 1 to 12 carbon atoms or an aryl.

20 7. Diarylalkene derivatives or diarylalkane derivatives represented by the following general formula (11), or pharmaceutically acceptable salts thereof:



wherein R^{28} represents an alkyl group having 1 to 12 carbon atoms, a cycloalkyl group having 3 to 12 carbon atoms or a cycloalkyl group which may have a hetero atom in the ring.

- 5 8. Diarylalkene derivatives or diarylalkane derivatives of the following general formula (1-A), or pharmaceutically acceptable salts thereof:



wherein A represents $-\text{CH}=\text{CH}-$, $-\text{CH}_2-\text{CH}_2-$ or $-\text{S}-$;

B represents $-(\text{CH}_2)_v-\text{CHR}^{21}$ wherein v represents 0 to 3, R^{21} represents

- 10 H, a lower alkyl, an aryl, a hydroxyl-lower alkyl, $-(\text{CH}_2)_w-\text{COOR}^{29}$ or $-(\text{CH}_2)_w-\text{NR}^{29}\text{R}^{30}$ wherein R^{29} and R^{30} each independently represent hydrogen atom or a lower alkyl group and w represents 0 to 4;


G represents $-(\text{CO})-$ or a covalent bond;

m represents 0 to 6; and


- 15 R^7 and R^8 each independently represent H, a lower alkyl, an aryl,

-(CO)R^{18a} wherein R^{18a} represents H, a lower alkyl, an aryl or a cycloalkyl group which may contain a hetero atom in the ring, or
 5 -(CO)OR²⁰ wherein R²⁰ represents an alkyl group having 1 to 12 carbon atoms, an aryl or a cycloalkyl group which may have a hetero atom in the ring.

9. Diarylalkene derivatives or diarylalkane derivatives of the following general formulae, or pharmaceutically acceptable salts thereof:







10. Diarylalkene derivatives or diarylalkane derivatives of the following general formulae, or pharmaceutically acceptable salts thereof:



11. A method for treating diseases selected from pain, brain injury caused by ischemia at the acute stage after the onset of cerebral
 15 infarction or cerebral hemorrhage, Alzheimer's disease, AIDS related

dementia, Parkinson's disease, progressive neurodegenerative diseases, neuropathy caused by head injury, bronchial asthma, unstable angina, irritable colitis or withdrawal symptoms after addiction to drugs, which comprises administering a diarylalkene derivative or a diarylalkane derivative of the following general formula (1), (2), (3) or (4), or a pharmaceutically acceptable salt thereof as the active ingredient to a patient in need of such treatment:



10 wherein A represents $-\text{CH}=\text{CH}-$, $-\text{CH}_2-\text{CH}_2-$, $-\text{S}-$, $-\text{CH}_2-\text{S}-$, $-\text{S}-\text{CH}_2-$, $-\text{O}-$, $-\text{CH}_2-\text{O}-$, $-\text{O}-\text{CH}_2-$, $-\text{N}(\text{R}^{17})-\text{CH}_2-$, $-\text{CH}_2-\text{N}(\text{R}^{17})-$, $-\text{CH}=\text{CH}-\text{CH}_2-$,

-CH₂-CH=CH-, -CH₂-CH₂-CH₂-, -N(R¹⁷)-(CO)-, -(CO)-N(R¹⁷)-, -(CO)-, -(SO)-, -C(R¹⁸R¹⁹)- wherein R¹⁷ represents H, a lower alkyl or an aryl, and R¹⁸ and R¹⁹ are each independently selected from the group consisting of H, a lower alkyl, an aryl and -C(O)OR¹⁵ wherein R¹⁵ represents a lower alkyl or an aryl;

5 a, b, c and d are each independently selected from the group consisting of CR¹ and CR²;
or one of a, b, c and d is N;

R¹, R², R³ and R⁴ each independently represent H, a halogen, -CF₃, -OR¹⁴,
10 -COR¹⁴, -SR¹⁴, -S(O)_t R¹⁵, -N(R¹⁴)₂, -NO₂, -OC(O)R¹⁴, -CO₂R¹⁴, -OCO₂R¹⁴,
-CN, -NR¹⁴COOR¹⁵, -SR¹⁵C(O)OR¹⁵ or -SR¹⁵N(R¹⁶)₂ wherein R¹⁴ represents H, a lower alkyl, an aryl or an aryl-lower alkyl group, R¹⁵ represents a lower alkyl or an aryl group, R¹⁶ is independently selected from the group consisting of H and -C(O)OR¹⁵, and t represents 1 or 2;

15 V-W represents C=C, CH-CH, CH-N or N-CH;

Z is selected from the group consisting of C, CH and N (with the proviso that when Z is C, the bond represented by a dotted line represents a double bond and when Z is CH or N, the bond represented by the dotted line represents a single bond);

20 n represents 0 to 3;

R⁵ and R⁶ each represent H, a halogen, -CF₃, a lower alkyl or an aryl;
or R⁵ and R⁶ together represent =O or =S;

Y¹ represents O or S;

B represents NR^{17a}, -NR^{17a}(CH₂)_vCHR²¹-, -(CH₂)_vCHR²¹- wherein v represents 0 to 3, R^{17a} represents H, a lower alkyl or an aryl, R²¹ represents H, a lower alkyl, an aryl, a hydroxyl-lower alkyl, -CH₂SH, -CH₂CH₂SCH₃, -CH₂(CO)NH₂, -CH₂CH₂(CO)NH₂, -(CH₂)_w-COOR²⁹,
25 -(CH₂)_w-NR²⁹R³⁰ wherein R²⁹ and R³⁰ each independently represent

hydrogen atom or a lower alkyl group, and w represents 0 to 4,
 $-(CH_2)_3NHC(NH_2)=NH$, benzyl, 4-hydroxybenzyl, 3-indoylmethyl or
 5-imidazolymethyl;


G represents $-(CO)-$, $-(SO)-$, $-(SO_2)-$ or a covalent bond;

5 m represents 0 to 6;

Y^2 represents C or S;

p and q are each independently selected from the group consisting of 1, 2
 and 3;

R^7 and R^8 each independently represent H, a lower alkyl, an aryl,
 10 $-(CO)R^{18a}$, $-(CS)R^{18a}$, $-(CO)NR^{18a}R^{19a}$, $-(CS)NR^{18a}R^{19a}$ wherein R^{18a}
 represents H, a lower alkyl, an aryl or a cycloalkyl group which may
 have a hetero atom in the ring, R^{19a} represents H, a lower alkyl or an
 aryl; or R^{18a} and R^{19a} together form a cycloalkyl which may have a
 halogen, $-CF_3$, a lower alkyl or an aryl as a substituent, $-(CO)OR^{20}$ or
 15 $-(CS)OR^{20}$ wherein R^{20} represents an alkyl group having 1 to 12 carbon
 atoms, an aryl, a cycloalkyl group which may have a hetero atom in the
 ring, an aryl-lower alkyl group, or a group of the following general
 formula (5):



(5)

20 wherein Y^4 and Y^3 each represent O or S; s represents 0 to 6;

E represents NR^{22} or CHR^{23} wherein R^{22} represents H, a lower alkyl or

an aryl; and R^{23} represents H, a lower alkyl, an aryl, a hydroxyl-lower alkyl, $-\text{CH}_2\text{SH}$, $-\text{CH}_2\text{CH}_2\text{SCH}_3$, $-\text{CH}_2(\text{CO})\text{NH}_2$, $-\text{CH}_2\text{CH}_2(\text{CO})\text{NH}_2$, $-\text{CH}_2\text{COOH}$, $-\text{CH}_2\text{CH}_2\text{COOH}$, $-(\text{CH}_2)_4\text{NH}_2$, $-(\text{CH}_2)_3\text{NHC}(\text{NH}_2)=\text{NH}$, benzyl, 4-hydroxybenzyl, 3-indoylmethyl or 5-imidazolymethyl;

5 R^{24} represents H, a lower alkyl or an aryl;


R^{25} represents H, a lower alkyl, an aryl, $-\text{OR}^{18a}$, $-(\text{CO})\text{R}^{18a}$, $-(\text{CS})\text{R}^{18a}$, $-(\text{CO})\text{NR}^{18a}\text{R}^{19a}$, $-(\text{CS})\text{NR}^{18a}\text{R}^{19a}$, $-(\text{CO})\text{OR}^{20}$ or $-(\text{CS})\text{OR}^{20}$ wherein R^{18a} , R^{19a} and R^{20} are as defined above,

10 R^9 represents H, a lower alkyl, an aryl, $-(\text{CO})\text{R}^{18a}$, $-(\text{CS})\text{R}^{18a}$, $-(\text{CO})\text{NR}^{18a}\text{R}^{19a}$, $-(\text{CS})\text{NR}^{18a}\text{R}^{19a}$, $-(\text{CO})\text{OR}^{20}$ or $-(\text{CS})\text{OR}^{20}$ wherein R^{18a} , R^{19a} and R^{20} are as defined above;

R^{10} represents H, a lower alkyl or an aryl;

R^{11} represents H, a lower alkyl or an aryl;

15 R^{12} represents H, a lower alkyl, an aryl, $-(\text{CO})\text{R}^{18a}$, $-(\text{CS})\text{R}^{18a}$, $-(\text{CO})\text{NR}^{18a}\text{R}^{19a}$, $-(\text{CS})\text{NR}^{18a}\text{R}^{19a}$, $-(\text{CO})\text{OR}^{20}$ or $-(\text{CS})\text{OR}^{20}$ wherein R^{18a} , R^{19a} and R^{20} are as defined above, or a substituent represented by the following general formula (6):



20 wherein s^1 represents 1 to 6;


Y^3 represents O or S,

R^{26} represents H, a lower alkyl or an aryl;

R^{27} represents H, a lower alkyl, an aryl, $-\text{OR}^{18a}$, $-(\text{CO})\text{R}^{18a}$, $-(\text{CS})\text{R}^{18a}$, $-(\text{CO})\text{NR}^{18a}\text{R}^{19a}$, $-(\text{CS})\text{NR}^{18a}\text{R}^{19a}$, $-(\text{CO})\text{OR}^{20}$ or $-(\text{CS})\text{OR}^{20}$ wherein R^{18a} ,

R^{19a} and R²⁰ are as defined above;

or R¹¹ and R¹² form a substituent represented by the following general formula (7) together with the nitrogen atom:



5 wherein Y³ represents O or S, and R²⁷ represents a group described above.

12. The method for treating diseases selected from pain, brain injury caused by ischemia at the acute stage after the onset of cerebral infarction or cerebral hemorrhage, Alzheimer's disease, AIDS related
10 dementia, Parkinson's disease, progressive neurodegenerative diseases, neuropathy caused by head injury, bronchial asthma, unstable angina, irritable colitis or withdrawal symptoms after addiction to drugs according to claim 11, which comprises administering the diarylalkene derivative or diarylalkane derivative of the general formula (1), (2), (3)
15 or (4), or pharmaceutically acceptable salt thereof, as the active ingredient to a patient in need of such treatment:

wherein the group represented by V-W is C=C, CH·CH or N·CH;

Z is selected from the group consisting of C, CH and N (with the proviso that when Z is C, the bond represented by a dotted line represents a
20 double bond and when Z is CH or N, the bond represented by the dotted line represents a single bond);

B represents NR^{17a}, CHR²¹ or CH₂CHR²¹ wherein R^{17a} represents H, a lower alkyl or an aryl, R²¹ represents H, a lower alkyl, an aryl, a

hydroxyl-lower alkyl, $-\text{CH}_2\text{SH}$, $-\text{CH}_2\text{CH}_2\text{SCH}_3$, $-\text{CH}_2(\text{CO})\text{NH}_2$,
 $-\text{CH}_2\text{CH}_2(\text{CO})\text{NH}_2$, $-\text{CH}_2\text{COOH}$, $-\text{CH}_2\text{CH}_2\text{COOH}$, $-(\text{CH}_2)_4\text{NH}_2$,
 $-(\text{CH}_2)_3\text{NHC}(\text{NH}_2)=\text{NH}$, benzyl, 4-hydroxybenzyl, 3-indoylmethyl or
5-imidazoymethyl; and

- 5 R^{18a} represents H, a lower alkyl or an aryl, and R^{19a} represents H, a
lower alkyl or an aryl; or R^{18a} and R^{19a} together form a cycloalkyl group
which may have a halogen, $-\text{CF}_3$, a lower alkyl or an aryl as a
substituent, and R^{25} and R^{27} each represent H, a lower alkyl, an aryl,
 $-(\text{CO})\text{R}^{18a}$, $-(\text{CS})\text{R}^{18a}$, $-(\text{CO})\text{NR}^{18a}\text{R}^{19a}$, $-(\text{CS})\text{NR}^{18a}\text{R}^{19a}$, $-(\text{CO})\text{OR}^{20}$ or
10 $-(\text{CS})\text{OR}^{20}$.

13. A method for treating diseases selected from pain, brain injury
caused by ischemia at the acute stage after the onset of cerebral
infarction or cerebral hemorrhage, Alzheimer's disease, AIDS related
dementia, Parkinson's disease, progressive neurodegenerative diseases,
15 neuropathy caused by head injury, bronchial asthma, unstable angina,
irritable colitis or withdrawal symptoms after addiction to drugs, which
comprises administering the diarylalkene derivative or diarylalkane
derivative, or pharmaceutically acceptable salt thereof according to claim
2 as the active ingredient to a patient in need of such treatment.

- 20 14. A method for treating diseases selected from pain, brain injury
caused by ischemia at the acute stage after the onset of cerebral
infarction or cerebral hemorrhage, Alzheimer's disease, AIDS related
dementia, Parkinson's disease, progressive neurodegenerative diseases,
neuropathy caused by head injury, bronchial asthma, unstable angina,
25 irritable colitis or withdrawal symptoms after addiction to drugs, which
comprises administering the diarylalkene derivative or diarylalkane
derivative, or pharmaceutically acceptable salt thereof according to claim
5 as the active ingredient to a patient in need of such treatment.

15. A method for treating diseases selected from pain, brain injury caused by ischemia at the acute stage after the onset of cerebral infarction or cerebral hemorrhage, Alzheimer's disease, AIDS related dementia, Parkinson's disease, progressive neurodegenerative diseases, neuropathy caused by head injury, bronchial asthma, unstable angina, irritable colitis or withdrawal symptoms after addiction to drugs, which comprises administering the diarylalkene derivative or diarylalkane derivative, or pharmaceutically acceptable salt thereof according to claim 7 as the active ingredient to a patient in need of such treatment.
16. A method for treating diseases selected from pain, brain injury caused by ischemia at the acute stage after the onset of cerebral infarction or cerebral hemorrhage, Alzheimer's disease, AIDS related dementia, Parkinson's disease, progressive neurodegenerative diseases, neuropathy caused by head injury, bronchial asthma, unstable angina, irritable colitis or withdrawal symptoms after addiction to drugs, which comprises administering the diarylalkene derivative or diarylalkane derivative, or pharmaceutically acceptable salt thereof according to claim 8 as the active ingredient to a patient in need of such treatment.
17. A method for treating diseases selected from pain, brain injury caused by ischemia at the acute stage after the onset of cerebral infarction or cerebral hemorrhage, Alzheimer's disease, AIDS related dementia, Parkinson's disease, progressive neurodegenerative diseases, neuropathy caused by head injury, bronchial asthma, unstable angina, irritable colitis or withdrawal symptoms after addiction to drugs, which comprises administering the diarylalkene derivative or diarylalkane derivative, or pharmaceutically acceptable salt thereof according to claim 9 as the active ingredient to a patient in need of such treatment.
18. A method for treating diseases selected from pain, brain injury

caused by ischemia at the acute stage after the onset of cerebral infarction or cerebral hemorrhage, Alzheimer's disease, AIDS related dementia, Parkinson's disease, progressive neurodegenerative diseases, neuropathy caused by head injury, bronchial asthma, unstable angina, irritable colitis or withdrawal symptoms after addiction to drugs, which comprises administering the diarylalkene derivative or diarylalkane derivative, or pharmaceutically acceptable salt thereof according to claim 10 as the active ingredient to a patient in need of such treatment.

19. A method for antagonizing N-type calcium channels, which comprises administering the diarylalkene derivatives or diarylalkane derivatives, or pharmaceutically acceptable salts thereof according to claim 11 as the active ingredient to a patient in need of such antagonistic action.

20. A pharmaceutical composition comprising the diarylalkene derivatives or diarylalkane derivatives, or pharmaceutically acceptable salts thereof according to claim 1 as the active ingredient, and pharmaceutically acceptable adjuvants.

21. A pharmaceutical composition comprising one of the diarylalkene derivatives, diarylalkane derivatives and pharmaceutically acceptable salts thereof according to claim 2 as the active ingredient, and pharmaceutically acceptable adjuvants.

22. A pharmaceutical composition comprising one of the diarylalkene derivatives, diarylalkane derivatives and pharmaceutically acceptable salts thereof according to claim 5 as the active ingredient, and pharmaceutically acceptable adjuvants.

23. A pharmaceutical composition comprising one of the diarylalkene derivatives, diarylalkane derivatives and pharmaceutically acceptable salts thereof according to claim 7 as the active ingredient, and

pharmaceutically acceptable adjuvants.

24. A pharmaceutical composition comprising one of the diarylalkene derivatives, diarylalkane derivatives and pharmaceutically acceptable salts thereof according to claim 8 as the active ingredient, and
5 pharmaceutically acceptable adjuvants.

25. A pharmaceutical composition comprising one of the diarylalkene derivatives, diarylalkane derivatives and pharmaceutically acceptable salts thereof according to claim 9 as the active ingredient, and pharmaceutically acceptable adjuvants.

10 26. A pharmaceutical composition comprising one of the diarylalkene derivatives, diarylalkane derivatives and pharmaceutically acceptable salts thereof according to claim 10 as the active ingredient, and pharmaceutically acceptable adjuvants.